5-Bromo-DMT (chemically designated as $2\\text{-(5-bromo-1H-indol-3-yl)-N,N-dimethylethanamine}$<\/span> or $5\\text{-bromo-N,N-dimethyltryptamine}$<\/span>) is an unlicensed synthetic and naturally occurring halogenated indole alkaloid belonging to the substituted tryptamine chemical class. Structurally, the molecule comprises an indole heterocycle substituted with a heavy bromine atom at the carbon-5 position of the benzene ring, coupled to an ethanamine side chain bearing two terminal N-methyl groups. Its empirical molecular formula is $\\text{C}_{12}\\text{H}_{15}\\text{BrN}_2$<\/span>, yielding an average molecular mass of approximately $267.17\\text{ g\/mol}$<\/span>. In nature, 5-Bromo-DMT represents an unusual halogenated marine natural product, initially isolated from marine sponges such as Smenospongia aurea<\/i> (formerly Aplysina aurea<\/i>) and Verongula gigantea<\/i>, alongside trace related bryozoan metabolites.<\/p>\n Finished preparations circulating in underground and research chemical markets are produced via total chemical synthesis (typically through the bromination of tryptamine cores or modified Speeter-Anthony tryptamine pathways). The substance is distributed as crystalline hydrochloride or hydrobromide salts ($\\text{HCl}$<\/span> \/ $\\text{HBr}$<\/span>) or as an amorphous lipophilic freebase intended for inhalation (vaporization) or insufflation.<\/p>\n Within the United Kingdom regulatory framework, 5-Bromo-DMT holds no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not catalogued in the British National Formulary (BNF) and holds no recognized status as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012. Under the Misuse of Drugs Act 1971 and the Misuse of Drugs Regulations 2001, 5-Bromo-DMT is categorized as a Class A, Schedule 1 controlled drug<\/b>. It falls under the universal generic structural definition governing substituted tryptamines (compounds structurally derived from tryptamine by substitution at the nitrogen or ring systems with specific alkyl or halogen additions), making its unauthorized possession, production, importation, and supply serious criminal offences. Commercial distribution occurs exclusively via illicit dark-web vendors, underground laboratories (UGLs), and unverified grey-market “research chemical” distributors, carrying critical clinical hazards of chemical non-sterility, synthesis by-products (e.g., residual heavy metal catalysts and elemental bromine species), and extreme active ingredient concentration variability.<\/p>\n The pharmacodynamic profile of 5-Bromo-DMT is governed by its interactions across central serotonin ($5\\text{-hydroxytryptamine}$<\/span> \/ $5\\text{-HT}$<\/span>) receptor subtypes, trace amine-associated receptors, and vesicular transporters:<\/p>\n Serotonin Receptor Subtype Binding and Partial Agonism:<\/b> 5-Bromo-DMT acts as a non-selective partial agonist across multiple central $5\\text{-HT}$<\/span> receptor families. Electrophysiological and radioligand binding assays indicate moderate affinity for the human $5\\text{-HT}_{2\\text{A}}$<\/span>, $5\\text{-HT}_{2\\text{C}}$<\/span>, and $5\\text{-HT}_{1\\text{A}}$<\/span> receptors:<\/p>\n $5\\text{-HT}_{2\\text{A}}$<\/span> Receptor Interaction:<\/b> Unlike its classical non-halogenated analogue $N,N\\text{-dimethyltryptamine}$<\/span> (DMT) or $5\\text{-MeO-DMT}$<\/span>, the introduction of a bulky, electronegative bromine atom at the 5-position significantly alters ligand docking within the orthosteric binding pocket of the $5\\text{-HT}_{2\\text{A}}$<\/span> receptor. This steric hindrance attenuates $G_{\\alpha q\/11}$<\/span>-coupled intracellular phospholipase C (PLC) activation and downstream inositol triphosphate ($\\text{IP}_3$<\/span>) \/ intracellular calcium flux. Consequently, while classical DMT is an intense visual and cognitive hallucinogen, 5-Bromo-DMT exhibits markedly lower psychedelic potency, failing to induce robust head-twitch responses (HTR) in rodent behavioral models.<\/p>\n<\/li>\n $5\\text{-HT}_{1\\text{A}}$<\/span> Receptor Agonism and Sedative Signalling:<\/b> 5-Bromo-DMT displays preferential, higher-affinity binding at central inhibitory $5\\text{-HT}_{1\\text{A}}$<\/span> somatodendritic autoreceptors and postsynaptic receptors coupled to the inhibitory $G_{\\alpha i\/o}$<\/span> protein pathway. Activation of $5\\text{-HT}_{1\\text{A}}$<\/span> suppresses adenylyl cyclase, lowers intracellular cAMP, and opens G-protein-coupled inwardly rectifying potassium (GIRK) channels. This hyperpolarizes serotonergic neurons within the dorsal raphe nucleus, arresting spontaneous neuronal firing and manifesting clinically as profound sedation, hypothermia, motor lethargy, and mild anxiolysis rather than overt psychedelic excitation.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Trace Amine-Associated Receptor 1 (TAAR1) and Monoamine Transporters:<\/b> In vitro evaluations demonstrate low-to-moderate binding at TAAR1 and weak inhibition of the serotonin transporter (SERT) and vesicular monoamine transporter 2 (VMAT2). Unlike amfetamines or synthetic cathinones, it does not act as a potent monoamine substrate-releasing agent, although high concentrations can elevate extracellular synaptic serotonin.<\/p>\n<\/li>\n Absence of Endocrine Feedback Interactions:<\/b> 5-Bromo-DMT exhibits negligible affinity for androgen, oestrogen, or progesterone nuclear receptors, exerting no direct steroidal or anabolic biological actions.<\/p>\n<\/li>\n<\/ul>\n 5-Bromo-DMT possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, placebo-controlled Phase I\u2013III clinical trials conforming to MHRA statutory criteria have ever evaluated 5-Bromo-DMT for human therapeutic safety, dosage tolerability, or clinical efficacy.<\/p>\n The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate 5-Bromo-DMT into any clinical management pathway. It is absent from guidelines governing major depressive disorder (NG222), anxiety disorders, addiction management, or palliative care. While licensed synthetic or botanical psychedelics (such as psilocybin) have entered regulated clinical research trials for treatment-resistant depression under strict Home Office Schedule 1 research licenses, 5-Bromo-DMT has never been licensed or advanced into formal UK academic clinical trials.<\/p>\n The practical application of 5-Bromo-DMT is confined entirely to non-clinical recreational drug use,<\/span> grey-market “biohacking” experimentation,<\/span> and natural product chemical extraction research.<\/span> In these unauthorized,<\/span> non-medical settings,<\/span> it is sought for:<\/span><\/p>\n Inducing mild,<\/span> non-visual altered states of consciousness characterized by somatic heaviness,<\/span> spatial relaxation,<\/span> and tranquil sedation.<\/span><\/p>\n<\/li>\n Anecdotal attempts to self-treat mood disorders,<\/span> treatment-resistant anxiety,<\/span> or cluster headaches without the intense,<\/span> overwhelming perceptual distortion associated with DMT or psilocybin.<\/span><\/p>\n<\/li>\n Chemical novelty exploration within online recreational drug subcultures.<\/span><\/p>\n<\/li>\n<\/ul>\n 5-Bromo-DMT holds no status within the NHS drug tariff,<\/span> cannot be prescribed on NHS prescription forms (FP10),<\/span> and must never be procured or administered for human medicinal purposes.<\/span><\/p>\n Human pharmacokinetic data for 5-Bromo-DMT are completely lacking; the pharmacokinetic parameters below represent clinical deductions based on its structural chemical characteristics and metabolic profiling of substituted tryptamines:<\/span><\/p>\n Absorption:<\/b><\/p>\n Oral Ingestion:<\/i> 5-Bromo-DMT exhibits low and erratic oral bioavailability when ingested in isolation,<\/span> as the unhindered primary side-chain tertiary amine is susceptible to extensive presystemic degradation by gastrointestinal and hepatic monoamine oxidase A (MAO-A).<\/span> However,<\/span> anecdotal consumer reports suggest the heavy bromine substitution may confer slight steric resistance against deamination compared to unsubstituted DMT,<\/span> permitting minor,<\/span> variable oral activity at higher doses.<\/span><\/p>\n<\/li>\n Inhalation (Vaporization of Freebase):<\/i> Rapidly absorbed across the vast pulmonary capillary bed into arterial circulation,<\/span> bypassing first-pass hepatic metabolism.<\/span> Onset of systemic and psychoactive effects occurs within 15 to 45 seconds post-inhalation,<\/span> reaching peak plasma concentrations (<\/span>$T_{max}$<\/span>) within 2 to 5 minutes.<\/span><\/p>\n<\/li>\n Insufflation (Hydrochloride Salt):<\/i> Absorbed across the vascular nasal mucosa,<\/span> with onset occurring within 5 to 10 minutes and peak titers achieved within 15 to 25 minutes.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n Distribution:<\/b> Following absorption,<\/span> 5-Bromo-DMT is moderately lipophilic due to the halogenated aromatic system.<\/span> It binds moderately to circulating human serum albumin and readily crosses the blood-brain barrier (BBB) via passive lipophilic transcellular diffusion to access central <\/span>$5\\text{-HT}$<\/span> receptor populations.<\/span> Its apparent volume of distribution (<\/span>$V_d$<\/span>) is estimated to be extensive,<\/span> partitioning into adipose tissue,<\/span> liver,<\/span> and brain parenchyma.<\/span><\/p>\n<\/li>\n Biotransformation:<\/b> In vivo,<\/span> 5-Bromo-DMT undergoes multi-pathway hepatic clearance:<\/span><\/p>\n Oxidative Deamination:<\/i> The primary clearance route is mediated by mitochondrial monoamine oxidase A (MAO-A),<\/span> cleaving the dimethylaminoethyl group into 5-bromoindole-3-acetaldehyde,<\/span> which is rapidly oxidized by aldehyde dehydrogenase (ALDH) into 5-bromoindole-3-acetic acid (5-BIAA).<\/span><\/p>\n<\/li>\n Cytochrome P450 and N-Demethylation:<\/i> Hepatic CYP450 isoenzymes (principally CYP2D6 and CYP3A4) mediate N-demethylation to yield 5-bromo-N-methyltryptamine (5-Br-NMT) and trace 5-bromotryptamine.<\/span><\/p>\n<\/li>\n N-Oxidation:<\/i> Flavin-containing monooxygenases (FMOs) and CYP450 mediate N-oxidation to form 5-Bromo-DMT-N-oxide.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n Elimination:<\/b> Systemic elimination is rapid,<\/span> occurring primarily via renal glomerular filtration and active tubular excretion of polar metabolites (5-BIAA and conjugated derivatives).<\/span> The biological duration of active physiological effects following vaporization is brief,<\/span> typically lasting between 20 and 45 minutes,<\/span> with an estimated plasma elimination half-life (<\/span>$t_{1\/2}$<\/span>) of approximately 30 to 60 minutes.<\/span> Trace brominated metabolites can remain detectable in specialized toxicological urine screens utilizing high-resolution liquid chromatography-tandem mass spectrometry (LC-MS\/MS) for 48 to 72 hours.<\/span><\/p>\n<\/li>\n<\/ul>\n The primary physiological effect reported in non-medical contexts is rapid somatic sedation,<\/span> motor relaxation,<\/span> perceptual slowing,<\/span> altered tactile sensation,<\/span> and mild auditory\/visual softening,<\/span> without the vivid kaleidoscopic imagery characteristic of classical tryptamines.<\/span> However,<\/span> its uncontrolled administration carries a distinct spectrum of acute multi-system adverse effects:<\/span><\/p>\n Neurological and Central Nervous System Disturbances:<\/b><\/p>\n Profound motor lethargy,<\/span> muscle weakness,<\/span> ataxia,<\/span> and loss of postural tone,<\/span> predisposing users to mechanical falls and physical trauma.<\/span><\/p>\n<\/li>\n Transient dysarthria (slurred speech),<\/span> confusion,<\/span> cognitive blunting,<\/span> and heavy somnolence.<\/span><\/p>\n<\/li>\n Paradoxical dysphoria,<\/span> depersonalization,<\/span> derealization,<\/span> acute panic attacks,<\/span> and feelings of respiratory depression (frequently experienced as a sensation of “forgetting to breathe” secondary to intense central <\/span>$5\\text{-HT}_{1\\text{A}}$<\/span> agonism).<\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n Autonomic and Cardiovascular Effects:<\/b><\/p>\n Transient,<\/span> mild-to-moderate sinus tachycardia or,<\/span> paradoxically,<\/span> sinus bradycardia (mediated by complex central <\/span>$5\\text{-HT}_{1\\text{A}}$<\/span>-driven vagal tone alterations).<\/span><\/p>\n<\/li>\n Systemic arterial hypertension or orthostatic hypotension:<\/span> fluctuating peripheral vascular resistance,<\/span> dizziness,<\/span> and postural syncope upon standing.<\/span><\/p>\n<\/li>\n Diaphoresis,<\/span> pupillary dilation (mydriasis),<\/span> and mild hypothermia.<\/span><\/p>\n<\/li>\n<\/ul>\n<\/li>\n Gastrointestinal and Mucosal Irritation:<\/b><\/p>\n Severe nausea,<\/span> dry heaving,<\/span> and emesis,<\/span> provoked by stimulation of <\/span>$5\\text{-HT}_3$<\/span> receptors within the solitary tract and area postrema.<\/span><\/p>\n<\/li>\n Intense burning, localized mucosal ulceration, and prolonged chemical rhinitis following nasal insufflation of halogenated salts.<\/p>\n<\/li>\n Pulmonary and bronchial irritation, acute coughing, and bronchospasm following the inhalation of pyrolyzed freebase vapors.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n Severe, Emergent and Life-Threatening Hazards (Rare to Toxicological Overdose):<\/b><\/p>\n Life-Threatening Serotonin Syndrome (Serotonin Toxicity):<\/b> Co-ingestion with monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), or serotonergic stimulants exponentially multiplies systemic serotonergic tone. This precipitates life-threatening serotonin toxicity, clinically defined by hyperthermia ($>39.0^\\circ\\text{C}$<\/span>), neuromuscular clonus, hyperreflexia, autonomic instability, and multiorgan failure.<\/p>\n<\/li>\n Aspiration and Asphyxiation:<\/b> Due to the rapid onset of profound sedation, motor immobility, and nausea, users who vomit while in a recumbent position face a severe, life-threatening risk of pulmonary aspiration of gastric contents, leading to chemical pneumonitis and fatal asphyxiation.<\/p>\n<\/li>\n Toxicological Contaminants of Synthetic Halogenated Tryptamines:<\/b> Unregulated synthesis of brominated indoles frequently generates toxic brominated reaction intermediates, free elemental bromine, and heavy metal residues, posing unknown long-term pulmonary, hepatic, and nephrotoxic liabilities.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n Given its illicit Class A legal status, lack of human safety data, and potent central serotonergic actions, 5-Bromo-DMT requires strict adherence to pharmacological contraindications and emergency harm-minimisation standards:<\/p>\n Contraindications:<\/b><\/p>\n Absolute Contraindication in All Humans:<\/b> The compound is an unauthorized, illicit chemical entity lacking any medicinal safety clearance.<\/p>\n<\/li>\n Concurrent Monoamine Oxidase Inhibitors (MAOIs):<\/b> Absolute contraindication with pharmaceutical MAOIs (e.g., phenelzine, tranylcypromine, moclobemide, selegiline) or botanical MAOIs (e.g., Peganum harmala<\/i>, Banisteriopsis caapi<\/i> harmala alkaloids). Inhibiting MAO-A halts the clearance of 5-Bromo-DMT, provoking severe, potentially fatal serotonin toxicity and hypertensive crises.<\/p>\n<\/li>\n Psychiatric Disorders:<\/b> Absolute contraindication in patients with schizophrenia, schizoaffective disorder, bipolar affective disorder, or a family history of psychosis (tryptamines trigger severe psychotic relapse, mania, or persistent hallucinogen persisting perception disorder [HPPD]).<\/p>\n<\/li>\n Cardiovascular Disease:<\/b> Contraindicated in coronary artery disease, uncontrolled hypertension, history of stroke, or cardiac arrhythmias.<\/p>\n<\/li>\n Severe Respiratory Disease:<\/b> Contraindicated in asthma, chronic obstructive pulmonary disease (COPD), or compromised airway reflexes (inhalation route carries acute bronchospasm risks).<\/p>\n<\/li>\n Pregnancy and Lactation:<\/b> Absolute contraindication; teratogenic, embryotoxic, and fetal developmental profiles are entirely uncharacterized.<\/p>\n<\/li>\n Paediatric Population:<\/b> Absolute contraindication in individuals under 18 years.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n2. Mechanism of Action and Pharmacodynamics<\/h2>\n
\n
\n
3. Approved UK Clinical Indications and Therapeutic Scope<\/h2>\n
\n
4. Pharmacokinetic Profile and Metabolic Fate<\/h2>\n
\n
\n
\n
5. Physiological Effects and Adverse Event Spectrum<\/h2>\n
\n
\n
\n
\n
\n
6. Contraindications, Drug Interactions, and Clinical Precautions<\/h2>\n
\n
\n